T Joseph Mattingly

Treatment tolerability associated with carboplatin dose based on actual versus adjusted body weight in patients with a body mass index ≥25 kg/m2 with advanced ovarian cancer

We sought to describe the treatment tolerability of carboplatin when dosed based on actual versus adjusted body weight in patients with a body mass index (BMI) ≥25 kg/m In this single-center, retrospective, descriptive analysis, we included patients with advanced-stage epithelial ovarian cancer who had a BMI ≥25 kg/m A total of 101 patients were included in this study: 61 in the actual body weight-based dosing group and 40 in the adjusted body weight-based dosing group. There was no significant difference in the incidence of treatment modifications between groups (73.8% vs 57.5%, p = .09). Dose reductions of carboplatin and treatment delays were more common in the actual body weight-based dosing group (39.3% vs 15.0%, p = .009) and (32.8 vs 5.0%, p = .001), respectively. Grade ≥3 neutropenia (19.7% vs 12.5%) and thrombocytopenia (13.1% vs 0.0%) were higher in the actual body weight group. More patients in the adjusted body weight-based dosing group initiated next-line therapy (55% vs 26.2%, p = .004). Median time to next treatment or death was not reached in the actual body weight-based dosing group but was 19.3 months (95% CI 12.4 to 24.0) in the adjusted body weight-based dosing group (HR 0.32, 95% CI 0.18 to 0.58, p = .0001). Death from any cause was lower in the actual body weight group (19.7% vs 60.0%, HR 0.35, 95% CI 0.18 to 0.71, p = .003). Dosing carboplatin using adjusted body weight in patients with a BMI ≥25 kg/m